Systemic Administration of siRNA via cRGD-containing Peptide

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Huang, Yuanyu ^a   Wang, Xiaoxia ^a   Huang, Weiyan ^a   Cheng, Qiang ^a   Zheng, Shuquan ^a   Guo, Shutao ^b   Cao, Huiqing ^a   Liang, Xing Jie ^b   Du, Quan ^a   Liang, Zicai ^a,c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^c School of Pharmaceutical Science and Technology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC ARGININE-GLYCINE-ASPARTIC ACID PEPTIDE; CYCLOPEPTIDE; RIBONUCLEASE; SMALL INTERFERING RNA;

AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CELL DEATH; CELL FRACTIONATION; CHEMISTRY; CONFOCAL MICROSCOPY; ENDOCYTOSIS; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; INTRACELLULAR SPACE; METABOLISM; MOLECULAR GENETICS; TISSUE DISTRIBUTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINO ACID SEQUENCE; ANIMALS; CELL DEATH; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOCYTOSIS; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; INTRACELLULAR SPACE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; PEPTIDES, CYCLIC; RIBONUCLEASES; RNA, SMALL INTERFERING; SUBCELLULAR FRACTIONS; TISSUE DISTRIBUTION;

EID: 84940093468     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12458     Document Type: Article

References (52)

1. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
2. Tabernero, J. et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3, 406-417 (2013).
3. Wooddell, C. I. et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 21, 973-985 (2013).
4. Geisbert, T. W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896-1905 (2010).
5. Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369, 819-829 (2013).
6. Nguyen, Q. D. et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 53, 7666-7674 (2012).
7. Patel, L. N., Zaro, J. L. & Shen, W. C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 24, 1977-1992 (2007).
8. Zhang, L.-X. & Zhang, S.-X. Mechanism of Cell-penetrating Peptides-mediated Internalization and Its Application. Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao 24, 1092-1096 (2008).
9. Divita, G. Bioactive cell-penetrating peptides: kill two birds with one stone. Chem Biol 17, 679-680 (2010).
10. Pujals, S., Fernandez-Carneado, J., Lopez-Iglesias, C., Kogan, M. J. & Giralt, E. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim Biophys Acta 1758, 264-279 (2006).
11. Morris, M. C., Deshayes, S., Heitz, F. & Divita, G. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell 100, 201-217 (2008).
12. Endoh, T. & Ohtsuki, T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 61, 704-709 (2009).
13. Holowka, E. P., Sun, V. Z., Kamei, D. T. & Deming, T. J. Polyarginine segments in block copolypeptides drive both vesicular assembly and intracellular delivery. Nat Mater 6, 52-57 (2007).
14. Gomez, J. A. et al. Cell-Penetrating Penta-Peptides (CPP5s): Measurement of Cell Entry and Protein-Transduction Activity. Pharmaceuticals (Basel) 3, 3594-3613 (2010).
15. Shah, P. P., Desai, P. R., Channer, D. & Singh, M. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release 161, 735-745 (2012).
16. Liu, X. et al. Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int J Pharm 448, 159-167 (2013).
17. Kumar, P. et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39-43 (2007).
18. Kim, S. S. et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 18, 993-1001 (2010).
19. Koivunen, E., Wang, B. & Ruoslahti, E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 13, 265-270 (1995).
20. Hood, J. D. & Cheresh, D. A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2, 91-100 (2002).
21. Cai, W., Gambhir, S. S. & Chen, X. Chapter 7. Molecular imaging of tumor vasculature. Methods Enzymol 445, 141-176 (2008).
22. Danhier, F., Le Breton, A. & Preat, V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 9, 2961-2973 (2012).
23. Varner, J. A. & Cheresh, D. A. Integrins and cancer. Curr Opin Cell Biol 8, 724-730 (1996).
24. Dechantsreiter, M. A. et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42, 3033-3040 (1999).
25. Kenny, L. M. et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 49, 879-886 (2008).
26. Morrison, M. S. et al. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 50, 116-122 (2009).
27. Schiffelers, R. M. et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32, e149 (2004).
28. Lee, J. H. et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl 48, 4174-4179 (2009).
29. Oba, M. et al. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alpha(v)beta(3) and alpha(v)beta(5) Integrins. Bioconjugate Chem 18, 1415-1423 (2007).
30. Waite, C. L. & Roth, C. M. PAMAM-RGD Conjugates Enhance siRNA Delivery Through a Multicellular Spheroid Model of Malignant Glioma. Bioconjugate Chem 20, 1908-1916 (2009).
31. Sakurai, Y. et al. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomalsiRNA system. J Control Release 173, 110-118 (2014).
32. Xiong, X. B., Uludag, H. & Lavasanifar, A. Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials 31, 5886-5893 (2010).
33. Holig, P. et al. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng Des Sel 17, 433-441 (2004).
34. Kato, M. & Mrksich, M. Using model substrates to study the dependence of focal adhesion formation on the affinity of integrinligand complexes. Biochemistry 43, 2699-2707 (2004).
35. Wu, P. et al. Imaging breast cancer cells and tissues using peptide-labeled fluorescent silica nanoparticles. J Nanosci Nanotechnol 8, 2483-2487 (2008).
36. Takayama, S. et al. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res 25, 79-83 (2005).
37. Zhao, Y. et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67, 5821-5830 (2007).
38. Liu, Z., Wang, F. & Chen, X. Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev Res 69, 329-339 (2008).
39. Kumar, C. C. Integrin alpha v beta 3as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4, 123-131 (2003).
40. Mitchell, D. J., Kim, D. T., Steinman, L., Fathman, C. G. & Rothbard, J. B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 56, 318-325 (2000).
41. Fuchs, S. M. & Raines, R. T. Pathway for polyarginine entry into mammalian cells. Biochemistry 43, 2438-2444 (2004).
42. Alghisi, G. C., Ponsonnet, L. & Ruegg, C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4, e4449 (2009).
43. Trikha, M. et al. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 62, 2824-2833 (2002).
44. Kamat, A. K., Rocchi, M., Smith, D. I. & Miller, O. J. Lamin A/C gene and a related sequence map to human chromosomes 1q12.1-q23 and 10. Somat Cell Mol Genet 19, 203-208 (1993).
45. Goldberg, M., Harel, A. & Gruenbaum, Y. The nuclear lamina: molecular organization and interaction with chromatin. Crit Rev Eukaryot Gene Expr 9, 285-293 (1999).
46. Shackleton, S. et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24, 153-156 (2000).
47. Chomoucka, J. et al. Magnetic nanoparticles and targeted drug delivering. Pharmacol Res 62, 144-149 (2010).
48. Aird, W. C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100, 158-173 (2007).
49. Wisse, E., Jacobs, F., Topal, B., Frederik, P. & De Geest, B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther 15, 1193-1199 (2008).
50. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. & Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65, 271-284 (2000).
51. Huang, Y. et al. Elimination pathways of systemically delivered siRNA. Mol Ther 19, 381-385 (2011).
52. Hong, J. et al. Comprehensive analysis of sequence-specific stability of siRNA. FASEB J 24, 4844-4855 (2010).